Scientific Publications

View publications containing scientific information about MiniMed technologies.

The MiniMedTM 780G system has been robustly studied across broad populations, including people who are naive to pump therapy and belong to diverse age groups, varying ranges  of starting therapy, and levels of glycemic control.1-3

This site will continue to be updated with the most current on-label publications.

 

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018

2024

First AuthorTitleAuthorsPediatric (Y/N)Epub MonthPublication Year
LaBlanche12-Month Real-Life Efficacy of the MiniMedTM 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study.Lablanche S, Delagenière J, Jalbert M, Sonnet E, Benichou M, Arnold N, Spiteri A, Le Berre JP, Renard E, Chevalier N, Borot S, Bonnemaison E, Coffin C, Teissier MP, Benhamou PY, Borel JC, Penfornis A, Joubert M, Kessler L.AdultFebruary2024
LandauA comparison of the usage of an open-source automated insulin delivery system and the MiniMedTM 780G system in children and adolescents with type 1 diabetes in real-world settings: the AWeSoMe study groupLandau Z, Lebenthal Y, Mazor-Aronovitch K, Brener A, Levek N, Jacobi-Polishook T, Ben Ari T, Abiri S, Haim A, Nir J, Rachmiel M, Pinhas-Hamiel O.PediatricJanuary2024
SegetGlycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system 2-year prospective, observational, two-center studySeget S, Chobot A, Tarasiewicz M, Bielawska A, Rusak E, Ochab A, Polanska J, Jarosz-Chobot P.PediatricFebruary2024
GardnerThe cost-effectiveness of an advanced hybrid closed loop system compared to standard management of type 1 diabetes in a Singapore setting.Gardner DSL, Lakkad M, Qiu Z, Inoue Y, Rama Chandran S, Wherry K.Cost-utility analysisMarch2024
RoyAn Automated Insulin Delivery System with Automatic Meal Bolus Based on a Hand-Gesturing AlgorithmRoy A, Grosman B, Benedetti A, Engheta B, Miller D, Laron-Hirsh M, Cohen Y, Ré R, Edd SN, Vigersky R, Cohen O, Tirosh A.AdultMarch2024
HalimAdvances in Automated Insulin Delivery with the MedtronicTM 780G: The Australian ExperienceHalim B, Abraham MB, Manos G, Arrieta A, Dai Z, Vogrin S, Lu J, MacIsaac R, Ekinci EI, Davis EA, Jenkins A, Shin J, Vigersky RA, Jones TW, O'Neal D.Pediatric/AdultMarch2024
LaBlanche12-Month Real-Life Efficacy of the MiniMedTM 780G Advanced Closed-Loop System in Patients Living with Type 1 Diabetes: A French Observational, Retrospective, Multicentric Study.Lablanche S, Delagenière J, Jalbert M, Sonnet E, Benichou M, Arnold N, Spiteri A, Le Berre JP, Renard E, Chevalier N, Borot S, Bonnemaison E, Coffin C, Teissier MP, Benhamou PY, Borel JC, Penfornis A, Joubert M, Kessler L.AdultFebruary2024
Atik-AltinokDoes MiniMedTM 780G insulin pump system affect energy and nutrient intake?: long-term follow-up studyAtik-Altinok Y, Mansuroglu Y, Demir G, Balki HG, Ozen S, Darcan S, Goksen D.Pediatric/AdultMarch2024
PetrovskiTwelve-Month Follow-up from a Randomized Controlled Trial of Simplified Meal Announcement Versus Precise Carbohydrate Counting in Adolescents with Type 1 Diabetes Using the MiniMedTM 780G Advanced Hybrid Closed-Loop SystemPetrovski G, Campbell J, Pasha M, Hussain K, Khalifa A, Umer F, Almajaly D, Hamdar M, Heuvel TVD, Edd SN.PediatricMarch2024
ChoudharyCelebrating the Data from 100,000 Real-World Users of the MiniMed™ 780G System in Europe, Middle East, and Africa Collected Over 3 Years: From Data to Clinical Evidence.Choudhary P, Arrieta A, van den Heuvel T, Castañeda J, Smaniotto V, Cohen O.Pediatric/AdultMarch2024
AkturkFuture of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery SystemsAkturk HK, Battelino T, Castañeda J, Arrieta A, van den Heuvel T, Cohen O.NAMarch2024
GrosmanA Peek Under the Hood: Explaining the MiniMed™ 780G Algorithm with Meal Detection Technology.Grosman B, Roy A, Lintereur L, Turksoy K, Benedetti A, Cordero TL, Vigersky RA, McVean J, Rhinehart AS, Cohen O.NAMarch2024
VigerskyThe Myth of MARD (Mean A bsolute R elative D ifference): Limitations of MARD in the Clinical Assessment of Continuous Glucose Monitoring DataVigersky RA, Shin J.NAMarch2024
GargDevelopment and Future of Automated Insulin Delivery (AID) SystemsGarg SK, McVean JJ.NAMarch2024
ForlenzaReducing Diabetes Burden in Medtronic's Automated Insulin Delivery SystemsForlenza GP, Dai Z, Niu F, Shin JJ.Pediatric/AdultMarch2024
BuckinghamDecreasing the Burden of Carbohydrate Counting and Meal Announcement with Automated Insulin Delivery, Meal Recognition, and Autocorrection Doses: A Case Study.Buckingham BA, Bergenstal RM.Pediatric Case ReportMarch2024
LingenRemoving Barriers, Bridging the Gap, and the Changing Role of the Health Care Professional with Automated Insulin Delivery SystemsLingen K, Maahs D, Bellini N, Isaacs D.NAMarch2024
ThrasherEarly Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United StatesThrasher JR, Arrieta A, Niu F, Cameron KR, Cordero TL, Shin J, Rhinehart AS, Vigersky RA.Pediatric/Adult
March2024
O'NealExercising Safely with the MiniMed™ 780G Automated Insulin Delivery SystemO'Neal DN, Zaharieva DP, Morrison D, McCarthy O, Nørgaard K.AdultMarch2024
ConsidineReal-World Evidence of Automated Insulin Delivery System Use.Considine EG, Sherr JL.Narrative review.March2024
BoucseinProtocol for a prospective, multicenter, parallel-group, open-label randomized controlled trial comparing standard care with Closed lOoP In chiLdren and yOuth with Type 1 diabetes and high-risk glycemic control: the CO-PILOT trialBoucsein A, Zhou Y, Haszard JJ, Jefferies CA, Wiltshire EJ, Styles SE, Crocket HR, Galland BC, Pasha M, Petrovski G, Paul RG, de Bock MI, Wheeler BJ.NAMarch2024
SinghEffects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 DiabetesSingh R, Imberg H, Ahmadi SS, Hallström S, Jendle J, Tengmark BO, Folino A, Marie E, Lind M.AdultMarch2024
CherubiniGlucometrics and device satisfaction in children and adolescents with type 1 diabetes using different treatment modalities: A multicenter real-world observational studyCherubini V, Fargalli A, Arnaldi C, Bassi M, Bonfanti R, Patrizia Bracciolini G, Cardella F, Dal Bo S, Delvecchio M, Di Candia F, Franceschi R, Maria Galassi S, Gallo F, Graziani V, Iannilli A, Mameli C, Marigliano M, Minuto N, Monti S, Mozzillo E, Pascarella F, Predieri B, Rabbone I, Roppolo R, Schiaffini R, Tiberi V, Tinti D, Toni S, Scaramuzza A, Vestrucci B, Gesuita R.PediatricMarch2024
Gómez MedinaCharacteristics Associated With Elevated Time Below Range in Elderly Patients With Type 1 Diabetes Using an Automated Insulin Delivery SystemGómez Medina AM, Parra Prieto DA, Henao Carrillo DC, Gómez CM, Muñoz Velandia OM, Caicedo S, Kerguelen Villadiego AL, Rodríguez Hortúa LM, Lucero Pantoja OD, Uribe Valencia M, García Guete MM, Robledo Gómez S, Rondón Sepúlveda M.AdultMarch2024
FernándezHealth-related quality of life in children with type 1 diabetes and advanced hybrid closed-loop systemsHuidobro Fernández B, Hevia Meana V, Ablanedo Mingot M, Costa Romero M.PediatricMarch2024
MesaImpact of an advanced hybrid closed-loop system on glycemic control throughout the menstrual cycle in women with type 1 diabetes prone to hypoglycemiaMesa A, Solà C, Vinagre I, Roca D, Granados M, Pueyo I, Cabré C, Conget I, Giménez M.AdultMarch2024
JalilovaThe psychosocial outcomes of advanced hybrid closed-loop system in children and adolescents with type 1 diabetesJalilova A, Pilan BŞ, Demir G, Özbaran B, Balkı HG, Arslan E, Köse SG, Özen S, Darcan Ş, Gökşen D.PediatricMarch2024
EvizAssessing the feasibility of time in tight range (TITR) targets with advanced hybrid closed loop (AHCL) use in children and adolescents: A single-centre real-world studyEviz E, Killi NE, Karakus KE, Can E, Gokce T, Yesiltepe Mutlu G, Hatun S.PediatricApril2024
NgLong-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetesNg SM, Wright NP, Yardley D, Campbell F, Randell T, Trevelyan N, Ghatak A, Hindmarsh PC.Pediatric
England National Health Service RWE
April2024
Al-SofianiReal-World Prospective Study of the Effectiveness and Safety of Automated Insulin Delivery Compared With Other Modalities of Type 1 Diabetes Treatment During Ramadan Intermittent FastingAl-Sofiani ME, Alharthi S, Albunyan S, Alzaman N, Klonoff DC, Alguwaihes A. April2024
ChristensenAutomated Insulin Delivery in Adults With Type 1 Diabetes and Suboptimal HbA1c During Prior Use of Insulin Pump and Continuous Glucose Monitoring: A Randomized Controlled TrialChristensen MB, Ranjan AG, Rytter K, McCarthy OM, Schmidt S, Nørgaard K.AdultApril2024
ForlenzaResponse to: MiniMed™ 780G System Outperforms Other Automated Insulin Systems Due to Algorithm Design, Not Bias-Response to Inaccurate AllegationsForlenza GP, Sherr JL.Response to ComentApril2024
van den HeuvelMiniMed™ 780G System Outperforms Other Automated Insulin Systems Due to Algorithm Design, Not Bias: Response to Inaccurate Allegationsvan den Heuvel T, Castaneda J, Thijs I, Arrieta A, Lintereur L, Shin J, Cohen O.CommentApril2024
GruberReal-Life Achievements of MiniMed™ 780G Advanced Closed-Loop System in Youth with Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective TrialGruber N, Wittenberg A, Brener A, Abiri S, Mazor-Aronovitch K, Yackobovitch-Gavan M, Averbuch S, Ben Ari T, Levek N, Levran N, Landau Z, Rachmiel M, Pinhas-Hamiel O, Lebenthal Y.PediatricMay2024
Beato-Vibora Beato-Víbora et al. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-World Setting. Beato-Víbora PI, Chico A, Moreno-Fernandez J, Bellido-Castañeda V, Nattero-Chávez L, Picón-César MJ, Martínez-Brocca MA, Giménez-Álvarez M, Aguilera-Hurtado E, Climent-Biescas E, Azriel-Mir S, Rebollo-Román Á, Yoldi-Vergara C, Pazos-Couselo M, Alonso-Carril N, Quirós C.Pediatric/AdultMay2024
Beato-ViboraResponse to Comment on Beato-Víbora et al. A Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world Setting. Diabetes Care 2024;47:216-224Beato-Víbora PI, Chico A, Moreno-Fernandez J, Bellido-Castañeda V, Nattero-Chávez L, Picón-César MJ, Martínez-Brocca MA, Giménez-Álvarez M, Aguilera-Hurtado E, Climent-Biescas E, Azriel-Mira S, Rebollo-Román Á, Yoldi-Vergara C, Pazos-Couselo M, Alonso-Carril N, Quirós C.NAMay2024
Bahillo-CuriesesUtility of time in tight range (TITR) in evaluating metabolic control in pediatric and adult patients with type 1 diabetes in treatment with advanced hybrid closed-loop systems.Bahillo-Curieses P, Fernández Velasco P, Pérez-López P, Vidueira Martínez AM, Nieto de la Marca MO, Díaz-Soto G.Pediatric/AdultMay2024
MesserRegarding Singh et al, "Effects, Safety, and Treatment Experience of Advanced Hybrid Closed-Loop Systems in Clinical Practice Among Adults Living With Type 1 Diabetes"Messer LH, Welsh JB, Habif S, Pinsker JE, Walker TC.NAJune2024
PassanisiSustained Effectiveness of an Advanced Hybrid Closed-Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes: A 1-Year Real-World StudyPassanisi S, Salzano G, Bombaci B, Minuto N, Bassi M, Bonfanti R, Scialabba F, Mozzillo E, Di Candia F, Monti S, Graziani V, Maffeis C, Piona CA, Arnaldi C, Tosini D, Felappi B, Roppolo R, Zanfardino A, Delvecchio M, Lo Presti D, Calzi E, Ripoli C, Franceschi R, Reinstadler P, Rabbone I, Maltoni G, Alibrandi A, Zucchini S, Marigliano M, Lombardo F; ISPED Diabetes Study Group Collaborators.PediatricJune2024
Olid-CárdenasReal-World Use of Hybrid Closed-Loop Systems during Diabetes Camp: A Preliminary Study for Secure Configuration Strategies in Children and AdolescentsOlid-Cárdenas MJ, Lendínez-Jurado A, Monroy-Rodríguez G, Gómez-Perea A, Cano-Ortiz A, Ariza-Jiménez AB, García-Ruiz A, Jiménez-Cuenca P, Picón-César MJ, Leiva-Gea I.PediatricJuly2024
SchiaffiniTime In Tight Range in children and adolescents with type 1 diabetes: A cross-sectional observational single centre study evaluating efficacy of new advanced technologiesSchiaffini R, Lumaca A, Martino M, Rapini N, Deodati A, Amodeo ME, Ciampalini P, Matteoli MC, Pampanini V, Cianfarani S.PediatricJuly2024
KesslerAdvanced Hybrid Closed Loop Algorithm Use in Type 1 Diabetes: The French MiniMed™ Glycemic Control and Quality of Life StudyLaurence Kessler, Charles Thivolet,Alfred Penfornis,Didier Gouet,Christine Coffin,Myriam Moret,Sophie Borot,Saïd Bekka,Emmanuel Sonnet,Michael Joubert,Sandrine Lablanche,Geoffrey Burtin,Fabio Di Piazza,Tim van den Heuvel,Ohad CohenPediatric/AdultNovember 20242024
PionaTime in tight range in automated insulin delivery system users: Real-world data from children and adolescents with type 1 diabetesPiona C, Passanisi S, Bombaci B, Marigliano M, Lombardo F, Mancioppi V, Morandi A, Maffeis C, Salzano G; ISPED Diabetes Study Group.PediatricJuly2024
ResminiImpact on Glycemia Risk Index and other metrics in type 1 adult patients switching to Advanced Hybrid Closed-Loop systems: a one-year real-life experienceResmini E, Zarra E, Dotti S, Rotondi G, Cornaghi AV, Madaschi S, Cimino E, Massari G, Pezzaioli LC, Buoso C, Sandri M, Girelli A.NAJuly2024
MinskySimplified Meal Management in Adults Using an Advanced Hybrid Closed-Loop SystemMinsky N, Shalit R, Benedetti A, Laron-Hirsh M, Cohen O, Kurtz N, Roy A, Grosman B, Tirosh A.NAAugust2024
ElbarbaryMiniMed™ 780G System Use in Type 1 Diabetes During Ramadan Intermittent Fasting: A Systematic Literature Review and Expert RecommendationsElbarbary N, Alguwaihes A, Zarif H, Hassanein M, Deeb A, Petrovski G, Al Dahash R, Alamoudi R, Hussain S, Ibrahim M, Shaikh S, Zainudin SB, Chaar W, van den Heuvel T, Al-Sofiani ME.NAAugust2024
MatejkoExcellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohortMatejko B, van den Heuvel T, Castaneda J, Arrieta A, Cyranka K, Cohen O, Małecki M, Klupa T.NAAugust2024
van den HeuvelGenerating real-world evidence on diabetes technology using the CareLink Personal data management systemvan den Heuvel T, Castañeda J, Arrieta A, Voelker B, Cohen O, Liu M, Diaz Garelli F, Shin J.NASeptember2024
Nigi12-Month Time in Tight Range Improvement with Advanced Hybrid-Closed Loop System in Adults with Type 1 DiabetesNigi L, Simon Batzibal MLA, Cataldo D, Dotta F.AdultSeptember2024
GomezTemporary Target Versus Suspended Insulin Infusion in Patients with Type 1 Diabetes Using the MiniMed 780G Advanced Closed-Loop Hybrid System During Aerobic Exercise: A Randomized Crossover Clinical TrialGómez AM, Henao DC, Muñoz OM, Romero DM, León JDS, Jaramillo PE, Moscoso E, Parra Prieto DA, Robledo S, Jaramillo MG, Rondón Sepúlveda M.AdultSeptember2024
BoucseinAutomated Insulin Delivery for Young People with Type 1 Diabetes and Elevated A1cBoucsein A, Zhou Y, Michaels V, Haszard JJ, Jefferies C, Wiltshire E, Paul RG, Parry-Strong A, Pasha M, Petrovski G, de Bock MI, Wheeler BJ.Pediatric/AdultSeptember2024
GeraldineExpert panel opinion on the optimal educational pathway for diabetes educators for training people with type 1 diabetes on the MiniMed™ 780G system: a Delphi consensus.Geraldine G, Alice R, Núria AC, Sima A, Virginie B, Vanessa B, Kerstin E, Francesca G, Audrey H, Amy J, Rea J, Anna SB, Paola C.NAOctober2024
DekkerTwelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care.Dekker P, van den Heuvel T, Arrieta A, Castañeda J, Mul D, Veeze H, Cohen O, Aanstoot HJ.Pediatric/AdultOctober2024
GawreckiNovel Protocol for the Use of Advanced Hybrid Closed-Loop System in Adolescents Engaged in Contact SportsGawrecki A, Chrzanowski J, Michalak A, Fendler W, Cohen O, Szadkowska A.PediatricOctober2024
WongExperiences of adolescents and young adults with type 1 diabetes and chronically elevated glucose levels following the transition from multiple daily injections to advanced hybrid closed-loop: A qualitative study. Wong JY, Styles SE, Wiltshire EJ, de Bock MI, Boucsein A, Palmer OJ, Wheeler BJ.Pediatric/AdultOctober2024
Nattero-ChávezComparing quality of life in traditional face-to-face visits with a hybrid approach of telemedicine with in-person follow-ups in recent users of advanced closed-loop systems: a randomized controlled clinical trial in patients with type 1 diabetesNattero-Chávez L, de La Calle E, Lecumberri-Pascual E, Bayona Cebada A, Ruiz Gracia T, Quintero Tobar A, Lorenzo Moñino M, Sánchez Rodríguez C, Izquierdo A, Escobar-Morreale HF, Luque-Ramírez M.AdultOctober2024
GargouriPrecision medicine in type 1 diabetes: comparing metabolic outcomes of Control-IQ and MiniMed™ 780G according to patient characteristicsGargouri I, Charfi H, Belabed W, Outenah C, Pochat A, Touimer M, Huynh P, Petit C, Lejeune M, Eroukhmanoff J, Ly Sall K, Penfornis A, Amadou C.Adult (>16 years)December2024
BorellaComparison of the night-time effectiveness in achieving glycemic targets in adults with type 1 diabetes of three advanced hybryd closed-loop systemsBorella ND, Ferramosca A, Castagna G, Ippolito S, Ceresoli S, Taverna A, Sonzogni B, Trevisan R, Lepore G.AdultNovember2024
LundemoseIs low-dose glucagon needed and effective in preventing fasted exercise-induced hypoglycaemia in type 1 diabetes treated with the MiniMed™ 780G, an automated insulin delivery system?Lundemose SB, McCarthy OM, Christensen MB, Laugesen C, Bracken RM, Holst JJ, Ranjan AG, Nørgaard K.AdultNovember2024
KogaiEffects of switching from MiniMed™ 640G to 770G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitusKogai T, Sato J, Yasuda H, Ayame T, Ozaki A, Takagi E, Koshibu M, Nishida Y, Ikeda F, Watada H.AdultNovember2024
GargouriPrecision medicine in type 1 diabetes: comparing metabolic outcomes of Control-IQ and MiniMed™ 780G according to patient characteristicsGargouri I, Charfi H, Belabed W, Outenah C, Pochat A, Touimer M, Huynh P, Petit C, Lejeune M, Eroukhmanoff J, Ly Sall K, Penfornis A, Amadou C.Pediatric/AdultDecember2024
Alguwaihes AMThe Use of MiniMed™ 780G System Is Associated With Stable Glycemic Control in People With Type 1 Diabetes Before, During, and After Ramadan: An Observational Study. Alguwaihes AM, Alotaibi N, Alotaibi M, Masry N, Safarini S.Pediatric/AdultJanuary2024
ZhouPredictors of glycaemic improvement in children and young adults with type 1 diabetes and very elevated HbA1c using the MiniMed™ 780G system.Zhou Y, Boucsein A, Michaels VR, Gray MK, Jefferies C, Wiltshire E, Paul RG, Parry-Strong A, Pasha M, Petrovski G, de Bock MI, Wheeler BJ.Pediatric/AdultJanuary2024
KiilavuoriChildren and adolescent with suboptimal control of type 1 diabetes improve during the first 2 years on automated insulin delivery system. Kiilavuori M, Varimo T, Tuomaala AK, Pulkkinen MA.PediatricJanuary2024
AbrahamGlycemic and Psychosocial Outcomes of Advanced Hybrid Closed-Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial. Abraham MB, Smith GJ, Dart J, Clarke A, Bebbington K, Fairchild JM, Ambler GR, Cameron FJ, Davis EA, Jones TW.PediatricJanuary2024
MoserThe use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Moser O, Zaharieva DP, Adolfsson P, Battelino T, Bracken RM, Buckingham BA, Danne T, Davis EA, Dovč K, Forlenza GP, Gillard P, Hofer SE, Hovorka R, Jacobs PG, Mader JK, Mathieu C, Nørgaard K, Oliver NS, O'Neal DN, Pemberton J, Rabasa-Lhoret R, Sherr JL, Sourij H, Tauschmann M, Yardley JE, Riddell MC.NAFebruary2024
McVeanHyperglycemia from Real World Dawn Phenomenon Is Nearly Eliminated with the MiniMed™ 780G SystemJennifer McVean, John Shin, Fang Niu, Franck Diaz-Garelli, Robert VigerskyPediatric/AdultJune2024
ShinSignificant Reduction in Real-World Nighttime Burden with the MiniMed™ 780G SystemJohn Shin, Zheng Dai, Naveen Mathew Nathan Sathiyanathan, Robert Vigersky, Jennifer McVeanPediatric/AdultJune2024
Kommareddi Cost-Effectiveness of the MiniMed™ 780G System vs. Multiple Daily Injections (MDI) Used with the Dexcom G6 Continuous Glucose Monitoring (CGM) SystemMallika Kommareddi, Robert VigerskyAdultJune2024
CastanedaTime in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed™ 780G SystemJavier Castaneda, Arcelia Arrieta, Tim van den Heuvel, Tadej Battelino, Ohad CohenPediatric/AdultJune2024
SehgalUse of a decision support tool and quick start onboarding tool in individuals with type 1 diabetes using advanced automated insulin delivery: a single-arm multi-phase intervention studyShekhar Sehgal, Martin De Bock, Benyamin Grosman, Jonathan Willman, Natalie Kurtz, Vanessa Guzman, Andrea Benedetti, Anirban Roy, Kamuran Turksoy, Magaly Juarez, Shirley Jones, Crla Frewen, Antony Watson, Barry Taylor, Benjamin WheelerAdultAugust2024
PollakovaAdvanced hybrid closed loop (artificial pancreas) and carbohydrate count in type 1 diabetesDaniela Pollakova, Angelo Lauria Pantano, Claudio Tubuli, Ugo Di Folco, Maria Rosaria NardoneAdultJune2024
BenedettiA Retrospective CGM-Driven Missed Meal Bolus Detection Tool Andrea Benedetti, Arthur Mikhno, Anirban Roy, John ShinPediatric/AdultJune2024
YangReal-world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta-analysisQin Yangm BBaoqi Zeng, Jiayi Hao, Qingping Yang, Feng Sun June2024
PassanisiSafety, Metabolic and Psychological Outcomes of Medtronic MiniMed™ 780G in Children, Adolescents and Young Adults: A Systematic ReviewStefano Passanisi, Fortunato Lombardo, Chiara Mameli, Bruno Bombaci, Maddalena Macedoni, Gianvincenzo Zuccotti, Klemen Dovc, Tadej Battelino, Giuseppina Salzano, Maurizio Delvecchio December2024
Al-SofianiThe MiniMed™ 780G automated insulin delivery system adapts to substantial changes in daily routine: Lessons from real world users during RamadanMohammed E. Al-Sofiani MD, Goran Petrovski MD, Abdulrahman Al Shaikh MD, Abdullah Alguwaihes MD, Mohammad Al Harbi MD, Dabia Al Mohannadi MD, Alero Adjene MD, Abdulmoeen Alagha MD, Sareea Al Remeithi MD, Naji Alamuddin MD, Arcelia Arrieta MSc, Javier Castañeda MSc, Wael Chaar PharmD, Tim van den Heuvel PhD, Ohad CohenMDAdultDecember2024
ElhenawyPerformance of the MiniMed™ 780G system on mitigating menstrual cycle-dependent glycaemic variabilityYasmine Ibrahim Elhenawy 1, Mohamed S Abdel Kader 2, Rasha A ThabetPediatricSeptember2024
Di MolfettaEfficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-AnalysisSergio Di Molfetta 1, Ludovico Di Gioia 1, Irene Caruso 1, Angelo Cignarelli 1, Suetonia C Green 2, Patrizia Natale 3 4 5, Giovanni F M Strippoli 3 4, Gian Pio Sorice 1, Sebastio Perrini 1, Annalisa Natalicchio 1, Luigi Laviola 1, Francesco Giorgino 1Pediatric/AdultSeptember2024
GallenExpert panel opinion on the optimal educational pathway for diabetes educators for training people with type 1 diabetes on the MiniMed™ 780G system: a Delphi consensusGeraldine Gallen 1, Alice Rosso 2, Núria Alonso-Carril 3, Sima Arbeli 4, Virginie Bahon 5, Vanessa Brown 6, Kerstin Endlich 7, Francesca Gulotta 8, Audrey Hansart 9, Amy Jolley 10, Rea Jussila 11, Anna Stefanowicz-Bielska 12 13, Paola Cardano October2024
GallenCorrection: Expert panel opinion on the optimal educational pathway for diabetes educators for training people with type 1 diabetes on the MiniMed™ 780G system: a Delphi consensusGeraldine Gallen 1, Alice Rosso 2, Núria Alonso-Carril 3, Sima Arbeli 4, Virginie Bahon 5, Vanessa Brown 6, Kerstin Endlich 7, Francesca Gulotta 8, Audrey Hansart 9, Amy Jolley 10, Rea Jussila 11, Anna Stefanowicz-Bielska 12 13, Paola Cardano December2024
HenryBeneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristicsZoé Henry 1, Sylvie Villar Fimbel 1, Nathalie Bendelac 1 2, Kevin Perge 2, Charles ThivoletPediatric/AdultOctober2024
KarakusInsulin Requirements for Basal and Auto-Correction Insulin Delivery in Advanced Hybrid Closed-Loop System: 4193 Days' Real-World Data of Children in Two Different Age GroupsKağan Ege Karakuş 1, Gül Yeşiltepe Mutlu 1 2, Tuğba Gökçe 2, Elif Eviz 2, Ecem Can 2, Serra Muradoğlu 2, Şükrü Hatun June2024
LeporeAdvanced Hybrid Closed-Loop System Achieves and Maintains Recommended Time in Range Levels for Up To 2 Years: Predictors of Best EfficacyGiuseppe Lepore 1, Nicolò Diego Borella 1, Giona Castagna 1 2, Silvia Ippolito 1, Silvia Bonfadini 1, Anna Corsi 1, Cristiana Scaranna 1, Alessandro Roberto Dodesini 1, Rosalia Bellante 1, Roberto TrevisanAdultJanuary2024

2023

First AuthorTitleAuthorsPediatric (Y/N)Epub MonthPublication Year
NgReal world use of hybrid-closed loop in children and young people with type 1 diabetes mellitus-a National Health Service pilot initiative in England.Ng SM, Wright NP, Yardley D, Campbell F, Randell T, Trevelyan N, Ghatak A, Hindmarsh PC.
PediatricDecember2023
SegetCommercial hybrid closed-loop systems available for a patient with type 1 diabetes in 2022Seget S, Tekielak A, Rusak E, Jarosz-Chobot P.----2023
CyrankaImprovement of Selected Psychological Parameters and Quality of Life of Patients With Type 1 Diabetes Mellitus Undergoing Transition From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to the MiniMed 780G Advanced Hybrid Closed-Loop System: Post hoc Analysis of a Randomized Control Study.Cyranka K, Matejko B, Juza A, Kieć-Wilk B, Krzyżowska S, Cohen O, Da Silva J, Lushchyk M, Malecki MT, Klupa T.AdultJanuary2023
PetrovskiSimplified Meal Announcement Versus Precise Carbohydrate Counting in Adolescents With Type 1 Diabetes Using the MiniMed 780G Advanced Hybrid Closed Loop System: A Randomized Controlled Trial Comparing Glucose ControlPetrovski G, Campbell J, Pasha M, Day E, Hussain K, Khalifa A, van den Heuvel T.PediatricJanuary2023
BassiOne-year follow-up comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes
Bassi M, Patti L, Silvestrini I, Strati MF, Ponzano M, Minuto N, Maggi D.
PediatricJanuary2023
BoucseinImpact of Advanced Hybrid Closed Loop on Youth With High-Risk Type 1 Diabetes Using Multiple Daily InjectionsBoucsein A, Watson AS, Frewen CM, Sanders OJ, Haszard JJ, Jones SD, Milford-Hughes PJ, de Bock MI, Wheeler BJ.PediatricMarch2023
KrzyżowskaLack of major impact of implementation of the Advanced Hybrid Closed Loop System in technologically-naïve patients with Type 1 Diabetes mellitus on their food choices or weight - a one year follow-upSabina Krzyżowska, Bartłomiej Matejko, Katarzyna Cyranka, Anna Juza, Beata Kieć-Wilk, Tomasz KlupaAdultMarch2023
McVeanEffect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical TrialMcVean J, Forlenza GP, Beck RW, Bauza C, Bailey R, Buckingham B, DiMeglio LA, Sherr JL, Clements M, Neyman A, Evans-Molina C, Sims EK, Messer LH, Ekhlaspour L, McDonough R, Van Name M, Rojas D, Beasley S, DuBose S, Kollman C, Moran A; CLVer Study Group.PediatricMarch2023
van den HeuvelAdvanced hybrid closed loop in adult population with type 1 diabetes: A substudy from the ADAPT randomized controlled trial in users of real-time continuous glucose monitoringvan den Heuvel T, Kolassa R, Keuthage W, Kroeger J, Ré R, de Portu S, Vorrink L, Shin J, Castañeda J, Vigersky R, Cohen O.AdultMarch2023
McCarthyGlycemia Around Exercise in Adults with Type 1 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A Switch Pilot Trial.McCarthy OM, Christensen MB, Kristensen KB, Schmidt S, Ranjan AG, Bain SC, Bracken RM, Nørgaard K.
AdultApril2023
SalzanoEditorial: Technologies for diabetesGiuseppina Salzano, Davide Tinti, Roque Cardona-Hernandez, Maurizio DelvecchioNAMay2023
Nattero-ChávezSwitching to an advanced hybrid closed-loop system in real-world practice improves hypoglycemia awareness and metabolic control in adults with type 1 diabetes, particularly in those with impaired perception of hypoglycemia symptomsNattero-Chávez L, Lecumberri Pascual E, De La Calle E, Bayona Cebada A, Ruiz T, Quintero Tobar A, Lorenzo M, Sánchez C, Izquierdo A, Luque-Ramírez M, Escobar-Morreale HF.AdultMarch2023
LombardoMiniMed™ 780G six-month use on children and adolescents with type 1 diabetes: clinical targets and predictors of optimal glucose controlLombardo F, Passanisi S, Alibrandi A, Bombaci B, Bonfanti R, Delvecchio M, Di Candia F, Mozzillo E, Piccinno E, Piona C, Rigamonti A, Scialabba F, Maffeis C, Salzano G.PediatricJune2023
GrassiReal-world performance of the MiniMed™ 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed™ automated insulin delivery systemGrassi B, Gómez AM, Calliari LE, Franco D, Raggio M, Riera F, Castro M, McVean J, van den Heuvel T, Arrieta A, Castañeda J, Cohen O.AdultMarch2023
BombaciReal-World Performance of First- Versus Second-Generation Automated Insulin Delivery Systems on a Pediatric Population With Type 1 Diabetes: A One-Year Observational StudyBombaci B, Passanisi S, Valenzise M, Macrì F, Calderone M, Hasaj S, Zullo S, Salzano G, Lombardo F.PediatricJuly2023
McCarthyAutomated Insulin Delivery Around Exercise in Adults with Type 1 Diabetes: A Pilot Randomized Controlled StudyMcCarthy OM, Christensen MB, Kristensen KB, Schmidt S, Ranjan AG, Bain SC, Bracken RM, Nørgaard K.AdultJuly2023
KesavadevReal-World User and Clinician Perspective and Experience with MiniMed™ 780G Advanced Hybrid Closed Loop SystemJothydev Kesavadev , Anjana Basanth, Gopika Krishnan, Arun Shankar, Geethu Sanal, Sunitha JothydevPediatricJune2023
Lendínez-JuradoImpact on glucometric variables and quality of life of the advanced hybrid closed-loop system in pediatric and adolescent type 1 diabetesLendinez-Jurado A, Gomez-Perea A, Ariza-Jimenez A, Tapia-Ceballos L, Becerra-Paz I, Martos-Lirio M, Moreno-Jabato F, Leiva-Gea IPediatricJune2023
RachmielMiniMed™ 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life ExperienceRachmiel M, Lebenthal Y, Mazor-Aronovitch K, Brener A, Levek N, Jacobi-Polishook T, Ben Ari T, Abiri S, Landau Z, Pinhas-Hamiel O.PediatricJune2023
AmigoSwitching from treatment with sensor augmented pump to hybrid closed loop system in type 1 diabetes: Impact on glycemic control and neuropsychological tests in the real worldAmigó J, Ortiz-Zúñiga Á, de Urbina AMO, Sánchez M, Dos-Santos M, Abad M, Cuadra F, Simó R, Hernández C, Simó-Servat O.AdultMay2023
CastañedaThe significance of coefficient of variation as a measure of hypoglycaemia risk and glycaemic control in real world users of the automated insulin delivery MiniMed™ 780G systemCastañeda J, Arrieta A, van den Heuvel T, Cohen O.Pediatric/Adult
May2023
CorderoGlycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 SensorCordero TL, Dai Z, Arrieta A, Niu F, Vella M, Shin J, Rhinehart AS, McVean J, Lee SW, Slover RH, Forlenza GP, Shulman DI, Pop-Busui R, Thrasher JR, Kipnes MS, Christiansen MP, Buckingham BA, Pihoker C, Sherr JL, Kaiserman KB, Vigersky RA.PediatricJune2023
MatejkoOne-Year Follow-Up of Advance Hybrid Closed-Loop System in Adults with Type 1 Diabetes Previously Naive to Diabetes Technology: The Effect of Switching to a Calibration-Free SensorMatejko B, Juza A, Kieć-Wilk B, Cyranka K, Krzyżowska S, Cohen O, Malecki MT, Klupa T.AdultJune2023
van den HeuvelLetter to the editor: Nuances from the manufacturer regarding the ABCD-DTN best practice guide on the use of MiniMed™ 780G Advanced Hybrid Closed Loop systemvan den Heuvel T, Castaneda J, Arrieta A, Cohen O.NAJuly2023
ElhenawySafety and efficacy of the structured onboarding steps and initiation protocol for MiniMed™ 780G system among an Egyptian cohort of young people living with type 1 diabetes.Elhenawy YI, Shaarawy MA, Selim EM. September2023
ElbarbaryMiniMed 780G™ advanced hybrid closed-loop system performance in Egyptian patients with type 1 diabetes across different age groups: evidence from real-world users.Elbarbary NS, Ismail EAR.Pediatric/AdultOctober2023
JendleA European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 DiabetesJendle J, Buompensiere MI, Ozdemir Saltik AZ, de Portu S, Smith-Palmer J, Pollock R, Cohen O.NAOctober2023
Navas MorenoPatient satisfaction in three advanced hybrid closed-loop systems at 6 months of treatment in adults with type 1 diabetes mellitus: a follow-up studyNavas Moreno V, Sebastian-Valles F, Sampedro-Nuñez M, Lahera Vargas M, Marazuela M, Arranz Martin JA.AdultOctober2023
SantovaAre all HCL systems the same? long term outcomes of three HCL systems in children with type 1 diabetes: real-life registry-based studySantova A, Plachy L, Neuman V, Pavlikova M, Petruzelkova L, Konecna P, Venhacova P, Skvor J, Pomahacova R, Neumann D, Vosahlo J, Strnadel J, Kocourkova K, Obermannova B, Pruhova S, Cinek O, Sumnik Z.PediatricOctober2023
HenryBeneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristicsHenry Z, Villar Fimbel S, Bendelac N, Perge K, Thivolet C.Pediatric/AdultOctober2023
EddTwelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetesEdd SN, Castañeda J, Choudhary P, Kolassa R, Keuthage W, Kroeger J, Thivolet C, Evans M, Ré R, Cellot J, de Portu S, Vorrink L, Shin J, van den Heuvel T, Cohen O; ADAPT study Group.AdultNovember2023
PihokerSafety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes.Pihoker C, Shulman DI, Forlenza GP, Kaiserman KB, Sherr JL, Thrasher JR, Buckingham BA, Kipnes MS, Bode BW, Carlson AL, Lee SW, Latif K, Liljenquist DR, Slover RH, Dai Z, Niu F, Shin J, Jonkers RAM, Roy A, Grosman B, Vella M, Cordero TL, McVean J, Rhinehart AS, Vigersky RA; MiniMed AHCL Study Group.PediatricNovember2023
Nigi12-Month Efficacy of Advanced Hybrid Closed-Loop System in Adult Type 1 Diabetes PatientsNigi L, Iraci Sareri G, Cataldo D, Dotta F.AdultNovember2023
Gómez MedinaResults From a Virtual Clinic for the Follow-up of Patients Using the Advanced Hybrid Closed-Loop SystemGómez Medina AM, Henao Carrillo DC, Silva León JD, Gómez González JA, Muñoz Velandia OM, Conde Brahim L, Mecón Prada GA, Rondón Sepúlveda M.AdultNovember2023
RossiDaytime hypoglycemic episodes during the use of an advanced hybrid closed loop system.

Rossi A, Montefusco L, Reseghetti E, Fabrizia Pastore I, Rossi G, Usuelli V, Loretelli C, Boci D, Ben Nasr M, D'Addio F, Bucciarelli L, Argenti S, Morpurgo P, Elena Lunati M, Fiorina P.AdultNovember2023
MichaelsGlucose and Psychosocial Outcomes 12 Months Following Transition from Multiple Daily Injections to Advanced Hybrid Closed Loop in Youth with Type 1 Diabetes and Suboptimal GlycemiaMichaels VR, Boucsein A, Watson AS, Frewen CM, Sanders OJ, Haszard JJ, Jones SD, Milford-Hughes PJ, de Bock MI, Wheeler BJ.PediatricNovember2023
Beato-ViboraA Multicenter Prospective Evaluation of the Benefits of Two Advanced Hybrid Closed-Loop Systems in Glucose Control and Patient-Reported Outcomes in a Real-world SettingBeato-Víbora PI, Chico A, Moreno-Fernandez J, Bellido-Castañeda V, Nattero-Chávez L, Picón-César MJ, Martínez-Brocca MA, Giménez-Álvarez M, Aguilera-Hurtado E, Climent-Biescas E, Azriel-Mir S, Rebollo-Román Á, Yoldi-Vergara C, Pazos-Couselo M, Alonso-Carril N, Quirós C.Pediatric/AdultNovember2023
PassanisiSafety, Metabolic and Psychological Outcomes of Medtronic MiniMed™ 780G in Children, Adolescents and Young Adults: A Systematic Review.
Passanisi S, Lombardo F, Mameli C, Bombaci B, Macedoni M, Zuccotti G, Dovc K, Battelino T, Salzano G, Delvecchio M.Pediatric/AdultDecember2023

2022

First AuthorTitleAuthorsPediatric (Y/N)Epub MonthPublication Year
PetrovskiSuccessful transitioning children and adolescents with type 1 diabetes from multiple daily injections to advanced hybrid closed-loop system in 10 days: a prospective intervention study on MiniMed™ 780G systemPetrovski G, Al Khalaf F, Campbell J, Day E, Almajaly D, Hussain K, Pasha M, Umer F, Hamdan M, Khalifa A.PediatricMay2022
de PortuRandomised controlled trial of Advanced Hybrid Closed Loop in an Adult Population with Type 1 Diabetes (ADAPT): study protocol and rationalede Portu S, Vorrink L, Re R, Shin J, Castaneda J, Habteab A, Cohen O.AdultFebruary2022
PetrovskiGlycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed™ 780G system in T1D individuals, previously treated with MDI).Petrovski G, Al Khalaf F, Campbell J, Day E, Almajaly D, Hussain K, Pasha M, Umer F, Hamdan M, Khalifa A.
PediatricMarch2022
ArrietaComparison of MiniMed™ 780G system performance in users aged younger and older than 15 years: Evidence from 12,870 real-world users.Arrieta A, Battelino T, Scaramuzza AE, Da Silva J, Castañeda J, Cordero TL, Shin J, Cohen O.
Pediatric/AdultJuly2022
PintaudiMinimed Medtronic 780G optimizes glucose control in patients with type 1 diabetes mellitus.

Pintaudi B, Gironi I, Nicosia R, Meneghini E, Disoteo O, Mion E, Bertuzzi F.AdultJuly2022
SchiaffiniComparison of two advanced hybrid closed loop in a pediatric population with type 1 diabetes: a real-life observational studySchiaffini R, Deodati A, Nicoletti MC, Carducci C, Ciampalini P, Lorubbio A, Matteoli MC, Pampanini V, Patera IP, Rapini N, Cianfarani S.PediatricJuly2022
KarakuşInsulin Requirements for Basal and Auto-Correction Insulin Delivery in Advanced Hybrid Closed-Loop System: 4193 Days' Real-World Data of Children in Two Different Age GroupsKarakuş KE, Yeşiltepe Mutlu G, Gökçe T, Eviz E, Can E, Muradoğlu S, Hatun Ş.PediatricJune2022
Beato-ViboraLong-term outcomes of an advanced hybrid closed-loop system: A focus on different subpopulationsBeato-Víbora PI, Ambrojo-López A, Fernández-Bueso M, Gil-Poch E, Javier Arroyo-Díez F.Pediatric/AdultAugust2022
ElbarbaryGlycemic control during Ramadan fasting in adolescents and young adults with type 1 diabetes on MiniMed™ 780G advanced hybrid closed loop system: A randomized controlled trial.Elbarbary NS, Ismail EAR.
Pediatric/AdultAugust2022
Grosman BIn Silico Evaluation of the Medtronic™ 780G System While Using the GS3 and Its Calibration-Free Successor, the Guardian™ 4 SensorGrosman B, Parikh N, Roy A, Lintereur L, Vigersky R, Cohen O, Rhinehart A.--September2022
Choudhary PAdvanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled studyChoudhary P, Kolassa R, Keuthage W, Kroeger J, Thivolet C, Evans M, Ré R, de Portu S, Vorrink L, Shin J, Habteab A, Castañeda J, da Silva J, Cohen O; ADAPT study Group.AdultSeptember2022
LeporeSwitching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.Lepore G, Rossini A, Bellante R, Corsi A, Scaranna C, Dodesini AR, Trevisan R.
AdultJuly2022
DovcImpact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop SystemsDovc K, Battelino T, Beck RW, Sibayan J, Bailey RJ, Calhoun P, Turcotte C, Weinzimer S, Smigoc Schweiger D, Nimri R, Bergenstal RM.Pediatric/AdultAugust2022
SegetProspective Open-Label, Single-Arm, Single-Center Follow-Up Study of the Application of the Advanced Hybrid Closed Loop System in Well-Controlled Children and Adolescents with Type 1 DiabetesSeget S, Rusak E, Polanska J, Jarosz-Chobot P.PediatricAugust2022
GianiniPatient reported outcome measures in children and adolescents with type 1 diabetes using advanced hybrid closed loop insulin deliveryGianini A, Suklan J, Skela-Savič B, Klemencic S, Battelino T, Dovc K, Bratina N.PediatricAugust2022
BombaciOne-Year Real-World Study on Comparison among Different Continuous Subcutaneous Insulin Infusion Devices for the Management of Pediatric Patients with Type 1 Diabetes: The Supremacy of Hybrid Closed-Loop SystemsBombaci B, Passanisi S, Alibrandi A, D'Arrigo G, Patroniti S, Averna S, Salzano G, Lombardo F.PediatricAugust2022
WeinzimerA Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670GWeinzimer SA, Bailey RJ, Bergenstal RM, Nimri R, Beck RW, Schatz D, Ambler-Osborn L, Schweiger DS, von dem Berge T, Sibayan J, Johnson ML, Calhoun P, Phillip M; FLAIR Study Group.Pediatric/Adult
April2022
AmuedoSuccessful Use of an Advanced Hybrid Closed-loop System in a Patient With Type 3c Pancreatogenic Diabetes Secondary to NesidioblastosisAmuedo S, Bellido V, Mangas Cruz MÁ, Gros Herguido N, López Gallardo G, Pérez Morales A, Soto Moreno A.AdultSeptember2022
MatejkoTransitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed™ 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.Matejko B, Juza A, Kieć-Wilk B, Cyranka K, Krzyżowska S, Chen X, Cohen O, Da Silva J, Malecki MT, Klupa T.
AdultNovember2022
SegetBody mass index, basal insulin and glycemic control in children with type 1 diabetes treated with the advanced hybrid closed loop system remain stable - 1-year prospective, observational, two-center study.Seget S, Jarosz-Chobot P, Ochab A, Polanska J, Rusak E, Witoszek P, Chobot A.
PediatricOctober2022
CastañedaPredictors of time in target glucose range in real-world users of the MiniMed™ 780G system.Castañeda J, Mathieu C, Aanstoot HJ, Arrieta A, Da Silva J, Shin J, Cohen O.
Pediatric/AdultAugust2022
PicciniLong-term effectiveness of advanced hybrid closed loop in children and adolescents with type 1 diabetes.Piccini B, Pessina B, Casalini E, Lenzi L, Toni S.
PediatricNovember2022

2021

First AuthorTitleAuthorsPediatric (Y/N)Epub MonthPublication Year
BergenstalA comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.Bergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D, Battelino T, Danne T, Weinzimer SA, Sibayan J, Johnson ML, Bailey RJ, Calhoun P, Carlson A, Isganaitis E, Bello R, Albanese-O'Neill A, Dovc K, Biester T, Weyman K, Hood K, Phillip M; FLAIR Study Group.Pediatric/Adult
January2021
CollynsImproved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes. Collyns OJ, Meier RA, Betts ZL, Chan DSH, Frampton C, Frewen CM, Hewapathirana NM, Jones SD, Roy A, Grosman B, Kurtz N, Shin J, Vigersky RA, Wheeler BJ, de Bock MI.Pediatric/AdultApril2021
RizziAdvanced hybrid closed-loop system: first successful clinical case after total pancreatectomy.Rizzi A, Tartaglione L, Di Leo M, Alfieri S, Pitocco D.AdultApril2021
WheelerImproved technology satisfaction and sleep quality with Medtronic MiniMed™ Advanced Hybrid Closed-Loop delivery compared to predictive low glucose suspend in people with Type 1 Diabetes in a randomized crossover trial. Wheeler BJ, Collyns OJ, Meier RA, Betts ZL, Frampton C, Frewen CM, Galland B, Hewapathirana NM, Jones SD, Chan DSH, Roy A, Grosman B, Kurtz N, Shin J, Vigersky RA, de Bock MI.Pediatric/AdultJanuary2021
Beato-ViboraAmelioration of user experiences and glycaemic outcomes with an Advanced Hybrid Closed Loop System in a real-world clinical setting. Beato-Víbora PI, Gallego-Gamero F, Ambrojo-López A, Gil-Poch E, Martín-Romo I, Arroyo-Díez FJ.AdultAugust2021
PetrovskiVirtual training on advanced hybrid closed-loop system MiniMed 780G in a teenager with type 1 diabetes previously treated with multiple daily injections: A case report. Petrovski G, Campbell J, Almajali D, Al Khalaf F, Hussain K.PediatricAugust2021
PicciniType 1 diabetes technology management traps in a pediatric patient: not all that glitters is gold.Piccini B, Casalini E, Macucci C, Toni S.PediatricJanuary2021
LeeFast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial. Lee MH, Paldus B, Vogrin S, Morrison D, Zaharieva DP, Lu J, Jones HM, Netzer E, Robinson L, Grosman B, Roy A, Kurtz N, Ward GM, MacIsaac RJ, Jenkins AJ, O'Neal DN.AdultAugust2021
Beato-ViboraRapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes. Beato-Víbora PI, Gallego-Gamero F, Ambrojo-López A, Gil-Poch E, Martín-Romo I, Arroyo-Díez FJ.Pediatric/AdultSeptember2021
Da SilvaReal-world Performance of the MiniMed™ 780G System: First Report of Outcomes from 4'120 Users.Da Silva J, Lepore G, Battelino T, Arrieta A, Castañeda J, Grosman B, Shin J, Cohen O.adultFebruary2021
HoodLived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives. Hood KK, Laffel LM, Danne T, Nimri R, Weinzimer SA, Sibayan J, Bailey RJ, Schatz D, Bratina N, Bello R, Punel A, Calhoun P, Beck RW, Bergenstal RM, Phillip M.Pediatric/Adult
October2021
CarlsonSafety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, VigerskyPediatric/AdultMarch2021
JendleThe Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. Jendle J, Buompensiere MI, Holm AL, de Portu S, Malkin SJP, Cohen O.Mean age >45 y
ped/adult
November2021
LambadiariCost-effectiveness analysis of an Advanced Hybrid Closed Loop insulin delivery system in people with type 1 diabetes in Greece. Lambadiari V, Ozdemir Saltik AZ, de Portu S, Buompensiere MI, Kountouri A, Korakas E, Sharland H, Cohen O.Mean age 33.8 y
ped/adult
May2021
BassiA Comparison of Two Hybrid Closed-Loop Systems in Italian Children and Adults With Type 1 DiabetesBassi M, Teliti M, Lezzi M, Iosca A, Strati MF, Carmisciano L, d'Annunzio G, Minuto N, Maggi D.Adults/PediatricJanuary2021
McVeanMiniMed™ 780G Insulin pump system with smartphone connectivity for the treatment of type 1 diabetes: overview of its safety and efficacyMcVean J, Miller J.--June2021

2020

First AuthorTitleAuthorsPediatric (Y/N)Epub MonthPublication Year
NimriFeasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses. Nimri R, Grosman B, Roy A, Nir J, Fisch Shvalb N, Kurtz N, Loewenthal N, Gillon-Keren M, Muller I, Atlas E, Phillip M. April2020

2019

First AuthorTitleAuthorsPediatric (Y/N)Epub MonthPublication Year
LeeGlucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study.Lee MH, Vogrin S, Paldus B, Jones HM, Obeyesekere V, Sims C, Wyatt SA, Ward GM, McAuley SA, MacIsaac RJ, Krishnamurthy B, Sundararajan V, Jenkins AJ, O'Neal DN. September2019
PaldusGlucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study. Paldus B, Lee MH, Jones HM, McAuley SA, Horsburgh JC, Roem KL, Ward GM, MacIsaac RJ, Cohen N, Colman PG, Jenkins AJ, O'Neal DN. January2019

2018

First AuthorTitleAuthorsPediatric (Y/N)Epub MonthPublication Year
de BockPerformance of Medtronic Hybrid Closed-Loop Iterations: Results from a Randomized Trial in Adolescents with Type 1 Diabetes. de Bock M, Dart J, Hancock M, Smith G, Davis EA, Jones TW.Mean age 15October2018

1. Arrieta A, et al. Diabetes  Obes Metab. 2022;10.1111/dom.14714
2. Choudhary P. et al, Lancet  Diabetes Endocrinol. 2022;  https://doi.org/10.1016/S2213-8587(22)00245-5
3. MatejkoB. et al, Diabetes Care. 2022; https://doi.org/10.2337/dc22-0470

Important Safety Information: MiniMed FlexTM system with SmartGuardTM technology with Simplera SyncTM sensor

The MiniMed FlexTM system is intended for the continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed FlexTM system includes SmartGuardTM technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.

The Simplera SyncTM sensor can be used one time and has a life up to 6 days, followed by a grace period of 24 hours. During the grace period, the sensor will continue to work as it did during the first 6 days, to allow the patient to change their sensor more flexibly. However, some sensors may not survive the full wear period for a variety of reasons. Please be prepared to replace the sensor during the grace period to ensure sensor glucose values continue to be monitored.

The Simplera SyncTM sensor is not intended to be used directly to make therapy adjustments while the MiniMed FlexTM system is operating in manual mode. All therapy adjustments in Manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Simplera SyncTM sensor. The Simplera SyncTM sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Simplera SyncTM sensor in the abdomen or other body sites, including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.

The Medtronic MiniMed FlexTM System consists of the following devices: MiniMed FlexTM Insulin Pump and the Simplera SyncTM sensor. The system requires a prescription from a healthcare professional.

WARNING: Do not use the SmartGuardTM feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuardTM feature.  

WARNING: Do not use the MiniMed FlexTM system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed FlexTM system.

WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuardTM feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.

Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed FlexTM system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including user guides and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, see https://bit.ly/MiniMedRisks.